The US Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor for adults with certain types of high cholesterol. Developed by Merck, the medication offers a convenient alternative for patients who need additional cholesterol-lowering treatment beyond statins, eliminating the need for injectable PCSK9 therapies.
